SUBCUTANEOUS TOCILIZUMAB MONOTHERAPY OR COMBINED WITH A CSDMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS: TOZURA, A POOLED ANALYSIS OF PHASE IV STUDIES IN 22 COUNTRIES

被引：2
|
作者：
Choy, E. [1 ]
Caporali, R. [2 ]
Xavier, R. [3 ]
Fautrel, B. [4 ]
Sanmarti, R. [5 ]
Bernasconi, C. [6 ]
Petho-Schramm, A. [6 ]
机构：
[1] Cardiff Univ, Cardiff, S Glam, Wales
[2] Univ Pavia, Pavia, Italy
[3] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil
[4] Pierre & Marie Curie Univ, Paris, France
[5] Univ Barcelona, Barcelona, Spain
[6] F Hoffmann La Roche & Cie AG, Basel, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.1615
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0199
引用
收藏
页码：847 / 848
页数：2
相关论文
共 50 条
  • [1] SUBCUTANEOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH A CSDMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS - INTERIM ANALYSIS OF A LARGE PHASE IV INTERNATIONAL UMBRELLA STUDY, "TOZURA"
    Choy, E.
    Caporali, R.
    Xavier, R.
    Fautrel, B.
    Sanmarti, R.
    Bernasconi, C.
    Petho-Schramm, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 509 - 510
  • [2] Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
    Choy, Ernest
    Caporali, Roberto
    Xavier, Ricardo
    Fautrel, Bruno
    Sanmarti, Raimon
    Bao, Min
    Bernasconi, Corrado
    Petho-Schramm, Attila
    [J]. RHEUMATOLOGY, 2018, 57 (03) : 499 - 507
  • [3] SUBCUTANEOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH A CSDMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS: 24 WEEKS RESULTS OF THE FRENCH PHASE IIIB STUDY, "TOSCA"
    Fautrel, B.
    Senbel, E.
    Vittecoq, O.
    Rist, S.
    Combe, B.
    Schaeverbeke, T.
    Liote, F.
    Flipo, R-M.
    Baffie, C.
    Pau, D.
    Fraga, E. Conde Da Silva
    Pinta, A.
    Gaudin, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1186 - 1187
  • [4] Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial
    Laura Bazzichi
    Francesca Nacci
    Luigi Sinigaglia
    Laura Bianchino
    Roberto Caporali
    [J]. Clinical Rheumatology, 2019, 38 : 841 - 849
  • [5] Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial
    Bazzichi, Laura
    Nacci, Francesca
    Sinigaglia, Luigi
    Bianchino, Laura
    Caporali, Roberto
    [J]. CLINICAL RHEUMATOLOGY, 2019, 38 (03) : 841 - 849
  • [6] Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries (vol 57, pg 499, 2018)
    Choy, Ernest
    Caporali, Roberto
    Xavier, Ricardo
    Fautrel, Bruno
    Sanmarti, Raimon
    Bao, Min
    Bernasconi, Corrado
    Petho-Schramm, Attila
    [J]. RHEUMATOLOGY, 2018, 57 (06) : 1129 - 1129
  • [7] Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
    Ogata, Atsushi
    Tanimura, Kazuhide
    Sugimoto, Toyohiko
    Inoue, Hiroshi
    Urata, Yukitomo
    Matsubara, Tsukasa
    Kondo, Masakazu
    Ueki, Yukitaka
    Iwahashi, Mitsuhiro
    Tohma, Shigeto
    Ohta, Shuji
    Saeki, Yukihiko
    Tanaka, Toshio
    [J]. ARTHRITIS CARE & RESEARCH, 2014, 66 (03) : 344 - 354
  • [8] Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
    Ogata, Atsushi
    Atsumi, Tatsuya
    Fukuda, Takaaki
    Hirabayashi, Yasuhiko
    Inaba, Masaaki
    Ishiguro, Naoki
    Kai, Motokazu
    Kawabata, Daisuke
    Kida, Daihei
    Kohsaka, Hitoshi
    Matsumura, Ryutaro
    Minota, Seiji
    Mukai, Masaya
    Sumida, Takayuki
    Takasugi, Kiyoshi
    Tamaki, Shigenori
    Takeuchi, Tsutomu
    Ueda, Atsuhisa
    Yamamoto, Kazuhiko
    Yamanaka, Hisashi
    Yoshifuji, Hajime
    Nomura, Akira
    [J]. ARTHRITIS CARE & RESEARCH, 2015, 67 (10) : 1354 - 1362
  • [9] Safety of tocilizumab in patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials
    Smolen, Josef S.
    Beaulieu, Andre D.
    Dikranian, Ara
    Fenton, Ira
    Fisheleva, Elena
    Alecock, Emma
    Emery, Paul
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S784 - S784
  • [10] SUBCUTANEOUS TOCILIZUMAB IN MONOTHERAPY OR IN COMBINATION WITH CSDMARD IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS: OBSERVATIONAL STUDY TO DESCRIBE REAL-WORLD DRUG RETENTION RATE AT 12 MONTHS
    Saraux, Alain
    Barnetche, Thomas
    Baudens, Guy
    Idier, Isabelle
    Delaporte, Flore
    Hilliquin, Pascal
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 725 - 726
12345